Loading
companiesCompany
LYSA (The Lymphoma Study Association)
aka LYSA, GELA, Groupe d'Etude des Lymphomes de l'Adulte, GOELAMS, LYSARC
The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.
Overview
LYSA was formed in 2012 by merging GELA (founded 1984) and GOELAMS; LYSARC is its academic research organisation. GELA's LNH-98.5 was the trial that added rituximab to CHOP and changed the outcome of DLBCL worldwide, and PRIMA established rituximab maintenance in follicular lymphoma. LYSA co-ran POLARIX (polatuzumab-R-CHP) and leads trials of bispecific antibodies, CAR-T sequencing and PET-guided therapy across France, Belgium and Portugal. It maintains a national lymphoma pathology review network (Lymphopath) and the REALYSA real-world cohort.
Headquarters
Pierre-Bénite (Lyon), FR
Scorecard
All companies#96of 1243 companies, score 51
- approved products +12
- targets +6
- modalities +4
- regions +6
- 24-month regulatory events +2
- registry trials +21
2 approved, 0 in phase 3, 0 earlier, 3 targets, 106 registry studies. Formula on the scorecards page.
Website
Founded
2012
Franck Morschhauser
President
LymphomaFollicular lymphomaImmunotherapy
Lille haematologist and President of LYSA, the French-Belgian lymphoma cooperative group, who led the RELEVANCE trial of chemotherapy-free therapy in follicular lymphoma.
Gilles Salles
Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center
Follicular lymphomaDiffuse large B-cell lymphomaAnti-CD20 antibodies
Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL.
Hervé Tilly
Professor of Hematology, Centre Henri Becquerel and University of Rouen; LYSA
Diffuse large B-cell lymphomaAntibody-drug conjugatesCooperative-group trials
Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years.
Steven Le Gouill
Director, Institut Curie Hospital Group; haematologist
LymphomaMantle cell lymphomaHospital leadership
Steven Le Gouill is a lymphoma specialist who leads the Institut Curie hospitals.
Notes
top- LNH-98.5 (R-CHOP)
- PRIMA (rituximab maintenance)
- POLARIX (with Roche)
- REALYSA cohort and Lymphopath
Similar pages
not linked directly; found by shared links- CompanyNordic Lymphoma Group
Shares International Extranodal Lymphoma Study Group, Hodgkin lymphoma, Monoclonal antibodies, Diffuse large B-cell lymphoma and the tag cooperative-group.
- CompanyHOVON
Shares German Lymphoma Alliance, International Extranodal Lymphoma Study Group, Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag cooperative-group.
- CompanyGerman Hodgkin Study Group
Shares German Lymphoma Alliance, FDG PET, Hodgkin lymphoma and the tag cooperative-group.
- CompanyUNICANCER
Shares Centre Henri Becquerel, Institut Curie and the tag cooperative-group.
- CompanyGerman Breast Group (GBG)
Shares Hodgkin lymphoma and the tag cooperative-group.
- CompanySWOG Cancer Research Network
Shares Hodgkin lymphoma and the tag cooperative-group.
- CompanyChildren's Oncology Group (COG)
Shares Hodgkin lymphoma and the tag cooperative-group.
- PersonChristiane Pott
Shares German Lymphoma Alliance and the tag cooperative-group.
cancers
2technologies
4drugs
2ApprovedCAR-T (CD19)
Axicabtagene ciloleucel · Yescarta
ApprovedBispecific T-cell engager (CD20×CD3, 2:1)
Glofitamab · Columvi